-
WHAT HEOR CAN LEARN FROM MATURE AI INDUSTRIES AND WHERE THE ANALOGIES BREAK DOWN
Mar 18, 2026, 21:38 PM -
REAL-WORLD MULTIPLE MYELOMA TREATMENT RESPONSES: EVALUATION OF FRONTLINE REGIMENS IN MELDTM LINKED MEDICARE, LABORATORY AND ELECTRONIC MEDICAL RECORDS...
Mar 18, 2026, 21:38 PM -
HEALTHCARE UTILIZATION PATTERNS AMONG MEDICARE BENEFICIARIES WITH FINANCIAL CONSTRAINTS
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB? VERSUS CYCLOSPORINE A IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY
Mar 18, 2026, 21:38 PM -
THE IMPACT OF ESKETAMINE ON ALZHEIMER’S DISEASE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER: A TARGET TRIAL EMULATION
Mar 18, 2026, 21:38 PM -
PREVALENCE OF CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AMONG OLDER WOMEN WITH BREAST CANCER IN THE 2011-2021 SEER-MEDICARE DATA
Mar 18, 2026, 21:38 PM -
INTEGRATION OF GENERATIVE ARTIFICIAL INTELLIGENCE INTO THE DEVELOPMENT OF STATISTICAL ANALYSIS PLANS FOR PATIENT-REPORTED OUTCOMES
Mar 18, 2026, 21:38 PM -
EVALUATING THE PERFORMANCE OF A GENERATIVE ARTIFICIAL INTELLIGENCE CHATBOT FOR ASSESSING SYSTEMATIC LITERATURE REVIEWS USING THE PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES 2020 CHECKLIST
Mar 18, 2026, 21:38 PM -
GENE THERAPY DEVELOPMENT PROGRAMS ARE BOTH GROWING AND EVOLVING IN THE FACE OF COMMERCIAL HEADWINDS
Mar 18, 2026, 21:38 PM -
MEDICATION-TAKING BEHAVIOUR IN ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD): A QUALITATIVE ANALYSIS OF SOCIAL MEDIA DATA
Mar 18, 2026, 21:38 PM -
ROLE OF REAL-WORLD EVIDENCE IN SUPPORTING AND VALIDATING CROSSOVER ADJUSTMENTS OF OVERALL SURVIVAL IN ONCOLOGY TRIALS: A SYSTEMATIC LITERATURE REVIEW OF HEALTH TECHNOLOGY ASSESSMENTS OF TREATMENTS FOR SELECTED TUMORS
Mar 18, 2026, 21:38 PM -
INCREASING UTILITY OF INTEGRATED REAL-WORLD EVIDENCE THROUGHOUT THE PRODUCT LIFECYCLE TO SUPPORT HEALTHCARE REIMBURSEMENT
Mar 18, 2026, 21:38 PM -
EFFECT OF ANTIHYPERTENSIVE USE ON FALL RISK
Mar 18, 2026, 21:38 PM -
USE OF A NEW INSTRUMENT TO ASSESS HEALTH-RELATED QUALITY OF LIFE IN CHILDREN 0-3 YEARS OF AGE DURING HOSPITALIZATION DUE TO ROTAVIRUS GASTROENTERITIS IN THE US
Mar 18, 2026, 21:38 PM -
ARE MEDICARE’S NEGOTIATED PRICES FOR APIXABAN AND RIVAROXABAN CONSISTENT WITH VALUE BASED PRICES? EVIDENCE FROM A SYSTEMATIC REVIEW OF U.S. COST-EFFECTIVENESS ANALYSES
Mar 18, 2026, 21:38 PM -
COST OF HEALTHCARE IN PATIENTS NEWLY DIAGNOSED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
Mar 18, 2026, 21:38 PM -
ESTIMATING THE COST OF ORPHAN DRUG TREATMENT FROM THE PERSPECTIVE OF MEXICO'S PUBLIC SECTOR
Mar 18, 2026, 21:38 PM -
A DECISION TREE ESTIMATING TOTAL COST OF CARE USING EXPOSURE-ADJUSTED DISCONTINUATION: CAPSAICIN 8% VERSUS ORAL TREATMENTS FOR PAINFUL DIABETIC NEUROPATHY IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
FLARE FREQUENCY, ORGAN DAMAGE, AND ECONOMIC BURDEN AMONG INDIVIDUALS WITH IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
CHALLENGES IN MACHINE LEARNING PREDICTION OF RARE EVENTS : IPW-ADJUSTED PREDICTORS AND THE ASSOCIATION OF GLP-1 RA WITH INCIDENT ALCOHOL-RELATED DISORDERS
Mar 18, 2026, 21:38 PM
